Edgewise Therapeutics, Inc. (EWTX)
44.22
-0.50
(-1.12%)
USD |
NASDAQ |
Aug 25, 16:00
44.22
0.00 (0.00%)
After-Hours: 19:59
Edgewise Therapeutics Enterprise Value : 4.363B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 4.363B |
| August 21, 2026 | 4.304B |
| August 20, 2026 | 4.209B |
| August 19, 2026 | 4.548B |
| August 18, 2026 | 4.297B |
| August 17, 2026 | 4.289B |
| August 14, 2026 | 4.303B |
| August 13, 2026 | 4.197B |
| August 12, 2026 | 4.238B |
| August 11, 2026 | 4.318B |
| August 10, 2026 | 4.348B |
| August 07, 2026 | 4.233B |
| August 06, 2026 | 4.330B |
| August 05, 2026 | 4.392B |
| August 04, 2026 | 4.361B |
| August 03, 2026 | 3.679B |
| July 31, 2026 | 3.685B |
| July 30, 2026 | 3.975B |
| July 29, 2026 | 3.827B |
| July 28, 2026 | 3.892B |
| July 27, 2026 | 4.026B |
| July 24, 2026 | 3.944B |
| July 23, 2026 | 3.777B |
| July 22, 2026 | 3.674B |
| July 21, 2026 | 3.809B |
| Date | Value |
|---|---|
| July 20, 2026 | 3.726B |
| July 17, 2026 | 3.828B |
| July 16, 2026 | 3.659B |
| July 15, 2026 | 3.943B |
| July 14, 2026 | 3.825B |
| July 13, 2026 | 3.991B |
| July 10, 2026 | 4.437B |
| July 09, 2026 | 4.754B |
| July 08, 2026 | 4.533B |
| July 07, 2026 | 4.191B |
| July 06, 2026 | 3.865B |
| July 02, 2026 | 3.807B |
| July 01, 2026 | 3.762B |
| June 30, 2026 | 3.922B |
| June 29, 2026 | 3.902B |
| June 26, 2026 | 3.960B |
| June 25, 2026 | 3.985B |
| June 24, 2026 | 4.051B |
| June 23, 2026 | 3.678B |
| June 22, 2026 | 3.427B |
| June 18, 2026 | 3.461B |
| June 17, 2026 | 3.247B |
| June 16, 2026 | 3.153B |
| June 15, 2026 | 3.289B |
| June 12, 2026 | 3.248B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cocrystal Pharma, Inc. | 14.40M |
| CNBX Pharmaceuticals, Inc. | 1.379M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 50.20M |
| Fulcrum Therapeutics, Inc. | -20.63M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -57.33M |
| Total Expenses (Quarterly) | 57.33M |
| EPS Diluted (Quarterly) | -0.5324 |
| Earnings Yield | -4.18% |
| Normalized Earnings Yield | -4.182 |